Power shifts in the global economy 
Former co-owner of Panama Papers law firm convicted of aiding and abetting tax evasion 
US Air Power’s Feet of Clay The World Health Organization announced on Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time.
Artemether-lumefantrine is the first antimalarial formulation designed specifically for the youngest victims of the mosquito-borne disease.
“The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy,” the WHO said in a statement.
Advertisement
Up to now, infants have been treated with formulations intended for older children – carrying a greater risk of dosage errors, side effects and toxicity.
“For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities,” WHO chief Tedros Adhanom Ghebreyesus said.
“But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide.
Advertisement
Don't Miss:
-
Hong Kong developers clear stock amid strong demand and shrinking supply
-
Underwhelming or underrated? DeepSeek V4 shows “impressive” gains
-
The real reason stock markets are still flying high despite grave risks
-
Hong Kong police bust motorcycle theft syndicate, arrest 5 over 14 cases
-
SCMP scoops 74 awards, led by Hong Kong fencing infographic in design competition